Dry Eye Disease Market Size Forecast to Reach 2034
DelveInsight has released a report forecasting the dry eye disease market and epidemiology, projecting market growth through 2034. The US market was the largest in 2023.
Market research firm DelveInsight has published a comprehensive analysis of the dry eye disease (DED) market, epidemiology, and market forecast through 2034. The report covers the United States, EU4 countries, the UK, and Japan.
In 2023, the United States represented the largest segment of the dry eye disease market, with an estimated size of $2,739 million. The US also recorded the highest number of diagnosed cases, approaching 22.5 million. Japan reported approximately 2.3 million male and 8.3 million female patients in 2023, with case numbers expected to increase.
Across the seven major markets (7MM), the total diagnosed prevalent cases of DED were approximately 55 million in 2023 and are projected to grow significantly by 2034. This anticipated rise in prevalence is expected to drive market expansion. Existing treatments, including VEVYE and EYSUVIS, along with other therapies, constituted a market of $3,759 million in 2023.
The report also highlights several emerging drugs in the development pipeline that could contribute to future market growth. These include PL9643 by Palatin Technologies, Reproxalap by Aldeyra Therapeutics, and AR-15512 by Alcon. Alcon also recently announced positive Phase III clinical trial results for its drug TRYPTYR™, positioning it as a potential novel neurosensory therapy for dry eye disease.